AMENDMENT AND RESPONSE Serial Number: 08/991,143

Filing Date: December 16, 1997

Title: METHODS TO TREAT UNDESIRABLE IMMUNE RESPONSES

Page 2 Dkt: 600.423US1

The amendment to page 64 of the specification adding a sequence identifier is made to conform the above-referenced application to the requirements of 37 C.F.R. § 1.821(d).

Applicant respectfully submits that the claims are in condition for allowance and notification to that effect is earnestly requested. The Examiner is invited to telephone Applicant's attorney (612-373-6959) to facilitate prosecution of this application.

If necessary, please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

Respectfully submitted,

BIANCA M. CONTI-FINE

By her Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. Box 2938
Minneapolis, MN 55402
(612) 373-6959

Date September 28, 2001

Janet E. Embretson

Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this Aday of September, 2001.

Name

Signature

Docket No. 00600.423US1

Clean Version of the Paragraph Beginning at Line 18, Page 64

METHODS TO TREAT UNDESIRABLE IMMUNE RESPONSES
Applicant: Bianca M. Conti-Fine
Serial No.: 08/991,143

Peptide Synthesis and Characterization. Three peptides, 19-20 residues in length, corresponding to residues 150-169, 181-200 and 360-378 of the TAChR α subunit (SEQ ID NO:3), were synthesized by methods described in Houghton (1985). An additional three 20 residue peptides were synthesized, corresponding to residues 271-290, 321-340, and 431-450 of diphtheria toxin (DTX). These peptides were shown to be highly and universally immunogenic for human CD4+ T cells (Yeh et al., 1990).